The Novel DNA Cross-Linking Agent KL-50 is Active Against Patient-Derived Models of New and Recurrent Post-Temozolomide Mismatch Repair-Deficient Glioblastoma

Medicine, Neurology, Oncology,
glioblastoma   DNA cross-linking agent   mismatch repair deficiency   temozolomide   KL-50   patient-derived xenograft models   novel therapy  

Breakthrough Study on KL-50 in Treating Recurrent Glioblastoma Background Glioblastoma (GBM) is a highly malignant brain tumor, particularly in patients with IDH wild-type (IDHwt), who have a very poor prognosis. Although the current standard treatment includes surgical resection, radiotherapy, and Temozolomide (TMZ) chemotherapy, most patients eve...